#United States #CAR-T therapy #Inceptor Bio #GRIT Bio #Morrisville

Strategic Alliance to Innovate CAR-T Treatments

In a significant move for cancer treatment, Inceptor Bio, a prominent player in cell therapy innovation, has announced a strategic partnership with GRIT Bio, a clinical-stage immunotherapy firm. The collaboration aims to expedite the development of IB-T101, an advanced CAR-T therapy aimed at solid tumors, utilizing the proprietary OUTLAST™ platform.

Targeting Unmet Medical Needs

IB-T101 is an autologous CD70 CAR-T program, designed to enhance T cell functionality in the challenging tumor microenvironment. This therapy specifically targets clear cell Renal Cell Carcinoma (ccRCC), a type of cancer that presents significant unmet medical needs, with over 300,000 new cases reported globally each year.

Dr. Matthias Schroff, the CEO of Inceptor Bio, expressed enthusiasm about the partnership, stating, "We are excited to partner with GRIT Bio to bring IB-T101 into the clinic and address the urgent need for effective solid tumor therapies." He further emphasized that the collaboration underscores the potential of the OUTLAST™ platform, which has shown promise in enhancing T cell characteristics crucial for combatting cancer.

Enhancing Clinical Development

With this partnership, GRIT Bio will gain exclusive rights to develop, manufacture, and commercialize IB-T101 in China. This collaboration promises to leverage the expertise of both companies, with GRIT bringing its drug development and manufacturing prowess to the forefront. Dr. Mengyang Chong, Chief Business Officer of GRIT Bio, commented on the unique opportunity, stating, "Partnering with Inceptor Bio allows us to bring a highly differentiated CAR-T program to patients. IB-T101 has the potential to transform the treatment landscape for solid tumors."

Agreement Details and Future Prospects

According to the partnership's terms, Inceptor Bio will benefit from milestone payments and royalties as IB-T101 meets specific developmental markers. This strategy not only focuses on immediate clinical advancements but also aims to harness clinical data from the partnership to support future regulatory submissions in various regions.

This collaborative effort is pivotal in advancing Inceptor Bio's goal to validate the OUTLAST™ platform as a leading method for engineered T cell therapies while ensuring accessible cancer treatments for patients worldwide.

About Inceptor Bio and GRIT Bio

Founded in May 2020, Inceptor Bio is dedicated to advancing innovative cell and gene therapies aimed at curing cancer. Leveraging its OUTLAST™ platform, the company focuses on addressing the unique challenges posed by solid tumors. The lead program, IB-T101, is designed to target the CD70 antigen seen in ccRCC, positioning it as a leading candidate in therapeutic solutions.

GRIT Bio, launched in 2019, specializes in developing transformative cell therapy products, particularly focusing on Tumor-Infiltrating Lymphocyte (TIL) therapies. The company utilizes its proprietary technologies—StemTexp®, StaViral®, KOReTIL®, and ImmuT Finder®—to create next-generation gene-edited treatments. With a skilled team and high-quality manufacturing capabilities, GRIT Bio is committed to addressing the urgent needs of patients battling solid tumors.

Through this partnership, both Inceptor Bio and GRIT Bio demonstrate their commitment to innovate and expand treatment options for those affected by cancer, potentially changing the narrative in solid tumor therapy.